February 13th 2023
Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.
January 23rd 2023
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
8th Annual School of Gastrointestinal Oncology® (SOGO®)
05/06/23 8:00 AM – 5:00 PM EDT
Expert Illustrations & Commentaries™: Targeting FGFR2b Overexpression in Advanced Gastric and GEJ Cancers
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
Clinical Vignettes™: Testing and Treatment Strategies in Cholangiocarcinoma
Advances In™: The Role of NRG1 Fusions Across Tumor Types
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Community Practice Connections™: 7th Annual School of Gastrointestinal Oncology®
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
FDA Lifts Clinical Hold on Trial Assessing CYAD-101 Plus Pembrolizumab and FOLFOX in Advanced CRCAugust 3rd 2022
Development on CYAD-101 as a treatment for patients with refractory/metastatic colorectal cancer continues after the FDA has lifted a clinical hold on the phase 1b CYAD-101-002 trial.
Tanios S. Bekaii-Saab, MD, on Potential of Dual Targeting to Transform Treatment of HER2+ CRCAugust 2nd 2022
At 2022 ASCO, Tanios S. Bekaii-Saab, MD, reviews the MOUNTAINEER trial of trastuzumab plus tucatinib for HER2-positive metastatic colorectal cancer and foreshadows how an approved regimen may help improve outcomes in this patient population.
Cornelis J. A. Punt, MD, PhD, Reviews Bevacizumab Plus Triplet or Doublet Chemo in Unresectable CRC Liver MetastasesJuly 31st 2022
Cornelis J. A. Punt, MD, PhD, spoke about the phase 3 CAIRO5 trial of bevacizumab plus either FOLFOXIRI or FOLFOX/FOLFIRI for patients with initially unresectable colorectal liver metastases.
Scenario 1: ctDNA to Determine Use of Adjuvant Chemotherapy in Stage II CRCJuly 28th 2022
Centering discussion on a patient scenario of stage II colorectal cancer, expert oncologists consider how ctDNA may inform use of adjuvant chemotherapy in this setting.
Neoadjuvant Immunotherapy Produces Promising Antitumor Response in Locally Advanced dMMR/MSI-H CRCJuly 25th 2022
Patients with mismatch repair deficient and/or microsatellite instability–high locally advanced colorectal cancer appear to derive promising benefit from treatment with neoadjuvant immune checkpoint inhibitors.
Heinz-Josef Lenz, MD, Describes Future Potential of CDC37 and MAOB as Predictors of Response in mCRCJuly 22nd 2022
The needle might be further pushed forward for precision medicine through exploration of novel proteins such as CDC37 and MAOB in patients with metastatic colorectal cancer.
Richard Kim, MD, Discusses Key Findings With Pembrolizumab Plus Chemo in Metastatic MSS/pMMR CRCJune 13th 2022
Richard Kim, MD, discussed key findings of the phase 1b KEYNOTE-651 trial, examining pembrolizumab plus standard chemotherapy in patients with microsatellite-stable or mismatch repair–proficient colorectal cancer.
Richard Kim, MD, Highlights the Rationale for Assessing Pembrolizumab Plus Standard Chemo in Metastatic MSS/pMMR CRCJune 10th 2022
During the 2022 American Society of Clinical Oncology Annual Meeting, Richard Kim, MD, discusses the rationale for the phase 1b KEYNOTE-651 trial examining pembrolizumab plus chemotherapy in metastatic colorectal cancer.
Colon Cancer Derives No OS Benefit With Primary Tumor Resection in Presence of Synchronous Unresectable MetastasesJune 7th 2022
In patients with colorectal cancer and synchronous unresectable metastases, resection of the primary tumor before systemic therapy did not result in an extension of overall survival.
Better Efficacy, Greater Toxicity Seen With Bevacizumab Plus FOLFOXIRI in Unresectable CRC Liver MetsJune 7th 2022
Bevacizumab plus FOLFOXIRI was superior to bevacizumab plus FOLFOX or FOLFIRI in terms of efficacy but was more toxic in certain patients with initially unresectable colorectal cancer liver metastases.
Prolonged PFS Observed With Addition of Atezolizumab to FOLFOXIRI and Bevacizumab for Metastatic CRCJune 2nd 2022
Atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and irinotecan resulted in a tolerable safety profile and improved progression-free survival vs the control regimen in patients with metastatic colorectal cancer.
Tucatinib Plus Trastuzumab Yields Positive Topline Data in Phase 2 MOUNTAINEER Trial for HER2+ mCRCMay 24th 2022
In the phase 2 MOUNTAINEER trial, patients with previously treated HER2-positive metastatic colorectal cancer who were treated with tucatinib plus trastuzumab were shown to have an improved objective response rate.